Clinical trial Recruiting at 1 site Observational Ages 9 to 50 Women only

Estimating the prevalence of high-risk HPV infections in women and girls across multiple countries

Official title: Global Burden Estimation of Human Papillomavirus (GLOBE-HPV)

Run by International Vaccine Institute · NCT06129253 · Data updated 2026-11-12

This study is trying to find out how common high-risk HPV infections are in girls and women aged 9-50 in different countries, especially in low-income areas.

More HPV Infection trials

Quick facts

Study typeObservational
Ages9 Years to 50 Years
SexWomen only
Enrollment29750 (estimated)
SponsorInternational Vaccine Institute
Academic / other
Locations8 sites (Dhaka and 7 other locations)
StatusRecruiting
StartedNovember 23, 2023
Main results expectedDecember 2027
Study endsDecember 2027
Registry record updatedJuly 16, 2025
Trial IDNCT06129253 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are girls and women aged 9-50 years residing in selected communities of the participating countries.

Probably not a fit

Patients who are not residents of the selected communities or those who decline to participate will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to estimate the point-prevalence of high-risk HPV infections among girls and women aged 9-50 years across eight countries, including South Asian and sub-Saharan African nations. It will utilize cross-sectional surveys and longitudinal studies to gather data on HPV incidence and risk factors, with a focus on low socio-economic populations. The study will implement a harmonized protocol to ensure comparability of data, while also adapting to country-specific contexts. Qualitative sub-studies will explore gender-related dynamics affecting HPV burden and access to prevention.

Why it matters

Potential benefit: If successful, this study could provide critical insights into the prevalence of high-risk HPV infections, informing public health strategies and interventions to reduce cervical cancer risk.

How similar studies have gone: Other studies have successfully estimated HPV prevalence in various populations, but this multi-country approach is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. 9 to 50 years old (for urban and rural CSSs) at the time of enrollment.
2. Resident in the selected community for at least the past 3 months (with the exception of pastoralists, refugees, and commercial sex workers).
3. Able to understand the purpose of the study and study procedures.
4. If aged 18 years or older or legally considered an emancipated minor, able and willing to provide consent to participate in the study including sample collection.
5. If aged \<18 years (and not considered an emancipated minor), supported in their participation by a parent or guardian who is able and willing to provide consent, and
6. If aged \<18 years (and not considered an emancipated minor), able and willing to provide assent to participate in the study.

Exclusion Criteria:

1. Decline consent to participate any activity of the study.
2. A medical condition or other reason, not directly related to HPV infection or HPV-related diseases, in the opinion of the investigator, precludes enrolment in the study.

Where it's running

  • Institut National pour la Recherche Biomedicale (INRB)
    Kinshasa, Democratic Republic of the Congo
    Recruiting
  • Diarrhoeal Disease Research, Bangladesh (icddr,b)
    Dhaka, Bangladesh
    Completed
  • University of Health and Allied Sciences (UHAS)
    Ho, Volta Region, Ghana
    Completed
  • Dhulikhel Hospital Kathmandu University Hospital (DHKUH)
    Dhulikhel, Nepal
    Completed
  • Aga Khan University (AKU)
    Karachi, Pakistan
    Completed
  • College of Medicine and Allied Health Sciences (COMAHS)
    Freetown, Sierra Leone
    Completed
Show 2 more locations
  • Mwanza Intervention Trial Unit (MITU)
    Mwanza, Tanzania
    Completed
  • Zambart
    Lusaka, Zambia
    Completed

Study contacts

  • Principal investigator: Alexandra Hill — Associate Research Scientist
  • Study coordinator: Julia Lynch
  • Email: julia.lynch@ivi.int
  • Phone: +8228811149

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.